

# **HEALTH INNOVATION WEST**

Market analysis of cluster strongholds and opportunities



April 2021, Gothenburg

## What we set out to do, and how we did it

#### **REPORT PURPOSE**

Anchored in industry needs and strategic focus:


1. Identify areas of excellence with industrial relevance where Health Innovation West has the potential to become world class

2. Create a fact-based updated overview of the life science cluster in West Sweden


3. Identify experienced challenges and improvement potential

#### METHODOLOGY

A data drive-approach combining quantitative and qualitative data



## Industry strongholds in healthcare facility products, pharmaceuticals and implants



The presence of big companies represents a key regional strength


Employees
2 225
1 844
863
512
482
• 201
• 154
• 95*

11 000 employees



480+

## Start-up companies focused on digital health and new drug development





## Elements in place for a world-class life science cluster



#### Addressing the challenges

#### 

*"My experience is that one wants to keep companies on arm's length distance."* 

#### "

"I do not even know how many biotech companies there are in Gothenburg ... I know more companies in Lund..."

#### "

"If I would go to Lindholmen with an idea about self-driving cars, people would come from all sides and want to get in. But there is no such vision in our area. People do not know about it"

# What could be the self-driving car of Life Science in West Sweden?

#### **Prioritized areas of excellence:**

- Mutual cross-sector potential and interest anchored in industrial needs
- Opportunity to leverage existing strongholds
- High impact areas fulfilling a Nordic need





## Materials science & Infection control

- Existing stronghold
- Key priority for many companies
- Need for partnering, accentuated during COVID-19 pandemic



1. Materials science & Infection contro 2. Regenerative medicine & ATMP


AstraZeneca


- Take position in growing field
- Available infrastructure and initiatives

Advanced Drug Delivery















## Overall conclusions: Potential exists. Now it's mode of execution\*



Possess elements necessary to become a world class life science cluster

The ecosystem is far from optimally utilized and challenges exists



A **built-up momentum** exists and expectation for **execution** 



Now about connecting people, execute and deliver short termsuccess and long-term enablers

\*... and this work has already started

Raising the ambition: Build recognition for <u>real</u> cross-sector collaboration

#### "Imagine if Western Sweden was known as the region where evidence is generated, where new innovation is adopted\*"

\*Quote heard during interviews

nferior Vena Cava ricuspid Valve Right Ventricle Yentricular Septum

Mitral Valve Papillary Muscle Left Ventricle

# Thank you! And let's make this happen!

Nordic office, HQ Gothenburg, Sweden triathlon.se Asia officeWest Europe officeTokyo, JapanLyon, Francetriathlongroup.jptriathlongroup.fr

East Europe office Moscow, Russia triathlongroup.ru North America office Dover, Delaware, USA triathlon.se Middle East office Muscat, Sultanate of Oman triathlon.se